Zexian Zeng
- Cancer Research top 1%
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 7
- Immunology top 2%
- Immune cells in cancer 7
- Molecular Biology top 2%
- Single-cell and spatial transcriptomics 6
- Biomedical Text Mining and Ontologies 6
- Gene expression and cancer classification 4
-
- AI in cancer detection 5
-
- Healthcare Operations and Scheduling Optimization 4
-
- Estrogen and related hormone effects 4
- Journals
- Nature (1 paper)Nucleic Acids Research (3 papers)Journal of Clinical Investigation (1 paper)
- Partner nations
- United StatesChinaPhilippines
In The Last Decade
Zexian Zeng
41 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Cancer Research 1.3k
- Pulmonary and Respiratory Medicine 1.7k
- Oncology 1.3k
- Immunology 1.0k
- Molecular Biology 2.8k
Countries citing papers authored by Zexian Zeng
This map shows the geographic impact of Zexian Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zexian Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zexian Zeng more than expected).
Fields of papers citing papers by Zexian Zeng
This network shows the impact of papers produced by Zexian Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zexian Zeng. The network helps show where Zexian Zeng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zexian Zeng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 11 | |
| 6 | 2023 | 12 | |
| 7 | Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-αbreakdown → | 2023 | 139 |
| 8 | 2022 | 17 | |
| 9 | 2022 | 14 | |
| 10 | 2022 | 26 | |
| 11 | 2022 | 5 | |
| 12 | 2022 | 1 | |
| 13 | 2021 | 23 | |
| 14 | 2020 | 13 | |
| 15 | 2019 | 67 | |
| 16 | 2019 | 27 | |
| 17 | 2019 | 23 | |
| 18 | 2018 | 56 | |
| 19 | 2018 | 23 | |
| 20 | 2017 | 136 |
About Zexian Zeng
Zexian Zeng is a scholar working on Emergency Medical Services, Cancer Research and Immunology, having authored 43 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Immune cells in cancer (7 papers), Single-cell and spatial transcriptomics (6 papers), Biomedical Text Mining and Ontologies (6 papers), AI in cancer detection (5 papers), Healthcare Operations and Scheduling Optimization (4 papers), Gene expression and cancer classification (4 papers) and Estrogen and related hormone effects (4 papers). The work is most often cited by research in Cancer Research (1.3k citations), Pulmonary and Respiratory Medicine (1.7k citations) and Oncology (1.3k citations). Zexian Zeng has collaborated with scholars based in United States, China and Philippines. Frequent co-authors include X. Shirley Liu, Jingxin Fu, Taiwen Li, Qianming Chen, Jing Li, Bo Li, David Cohen, Yuan Luo, Xiaoyu Li and Patrick T. Ellinor. Their work appears in journals such as Nature, Nucleic Acids Research and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.